At the news
? BEARISHIMPACT 5/10 PRESS-RELEASE filed Nov 12, 2026 at 07:30 ET
CorMedix reported Q3 2026 consolidated revenue of $54.5M, above consensus of $52.8M, but GAAP net loss of $14.7M ($-0.19 per share) versus consensus EPS of $-0.11. Adjusted EBITDA was $3.1M. Revenue declined 48% YoY due to DefenCath's post-TDAPA pricing transition. The company maintained FY 2026 revenue guidance of $325-$345M and narrowed adjusted EBITDA guidance to $130-$140M. The pending Heron Therapeutics asset acquisition adds four commercial products and is expected to close in Q1 2027.
- Q3 2026 consolidated revenue $54.5M, above consensus $52.8M but down 48% YoY from $104.3M
- GAAP net loss $14.7M ($-0.19 per share) vs consensus EPS $-0.11; prior year net income $108.6M
- Adjusted EBITDA $3.1M, down from $71.9M in Q3 2025
- DefenCath sales $17.2M, down from prior year due to post-TDAPA pricing transition
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access